Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Craig S. Pace"'
Autor:
Hannah J. Barbian, Julie M. Decker, Frederic Bibollet-Ruche, Rachel P. Galimidi, Anthony P. West, Gerald H. Learn, Nicholas F. Parrish, Shilpa S. Iyer, Yingying Li, Craig S. Pace, Ruijiang Song, Yaoxing Huang, Thomas N. Denny, Hugo Mouquet, Loic Martin, Priyamvada Acharya, Baoshan Zhang, Peter D. Kwong, John R. Mascola, C. Theo Verrips, Nika M. Strokappe, Lucy Rutten, Laura E. McCoy, Robin A. Weiss, Corrine S. Brown, Raven Jackson, Guido Silvestri, Mark Connors, Dennis R. Burton, George M. Shaw, Michel C. Nussenzweig, Pamela J. Bjorkman, David D. Ho, Michael Farzan, Beatrice H. Hahn
Publikováno v:
mBio, Vol 6, Iss 2 (2015)
ABSTRACT Broadly cross-reactive neutralizing antibodies (bNabs) represent powerful tools to combat human immunodeficiency virus type 1 (HIV-1) infection. Here, we examined whether HIV-1-specific bNabs are capable of cross-neutralizing distantly relat
Externí odkaz:
https://doaj.org/article/46821e94c4f84dc3b70247c0404d431a
Autor:
Brian Moldt, Abishek Chandrashekar, Erica N Borducchi, Joseph P Nkolola, Heather Stephenson, Mark Nagel, Magdeleine Hung, Joshua Goldsmith, Craig S Pace, Brian Carr, Nathan D Thomsen, Wade S Blair, Romas Geleziunas, Dan H Barouch
Publikováno v:
PLoS Pathogens, Vol 18, Iss 4, p e1010467 (2022)
A key challenge for the development of a cure to HIV-1 infection is the persistent viral reservoir established during early infection. Previous studies using Toll-like receptor 7 (TLR7) agonists and broadly neutralizing antibodies (bNAbs) have shown
Externí odkaz:
https://doaj.org/article/e3641d8b3dd440928d664b109fe6371d
Autor:
Craig S. Pace, Romas Geleziunas, Mini Balakrishnan, Aiyappa Parvangada, Dominique L Braun, Nathan D. Thomsen, Huldrych F. Günthard, Herbert Kuster, Brian Moldt, Christian Callebaut, Sean E Collins, Ross Martin
Publikováno v:
Journal of acquired immune deficiency syndromes (1999). 88(1)
BACKGROUND HIV envelope (env) diversity represents a significant challenge for the use of broadly neutralizing antibodies (bNAbs) in HIV treatment and cure studies. Screening for viral sensitivity to bNAbs to select eligible trial participants will b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2f4321f1eedaea66d97bc2a0357cf0a0
https://pubmed.ncbi.nlm.nih.gov/34397744
https://pubmed.ncbi.nlm.nih.gov/34397744
Autor:
Craig S. Pace, Kim J. Hasenkrug, Ulf Dittmer, Sekar Natesampillai, Kathrin Sutter, Marek Widera, Dakota L. Pouncey, Brent Race, Kerry J. Lavender, Katie Phillips, Nathan W. Cummins, Joshua Goldsmith, George Kukolj, Ronald J. Messer, Jim Zheng, Erik Van Dis
Publikováno v:
AIDS. 32:1-10
Although bone marrow, liver, thymus (BLT)-humanized mice provide a robust model for HIV-1 infection and enable evaluation of cure strategies dependent on endogenous immune responses, most mice develop graft versus host disease (GVHD), limiting their
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::597b3ce21137dafb0dc0c139222231b6
https://doi.org/10.1097/qad.0000000000001674
https://doi.org/10.1097/qad.0000000000001674
Autor:
Michael S. Seaman, David D. Ho, Ming Sun, Amos Wu, Qing Fang, Craig S. Pace, Chasity D. Andrews, Ruijiang Song, Neal N. Padte
Publikováno v:
JAIDS Journal of Acquired Immune Deficiency Syndromes. 73:365-373
BACKGROUND Preexposure prophylaxis using antiretroviral agents has been shown to effectively prevent human immunodeficiency virus type 1 (HIV-1) acquisition in high-risk populations. However, the efficacy of these regimens is highly variable, which i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::34e1075c1da31652731312b9606d802b
https://doi.org/10.1097/qai.0000000000001119
https://doi.org/10.1097/qai.0000000000001119
Monoclonal antibodies to host cellular receptors for the treatment and prevention of HIV-1 infection
Autor:
Craig S. Pace, Martin Markowitz
Publikováno v:
Current Opinion in HIV and AIDS. 10:144-150
PURPOSE OF REVIEW Clinically relevant monoclonal antibodies (mAb) to host cellular receptors have been generated to both the CD4 receptor and the CCR5 coreceptor, cell surface proteins critical for HIV-1 entry. Ibalizumab is a novel humanized mAb tha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::22634999f0f0669abeb5b937b13be824
https://doi.org/10.1097/coh.0000000000000146
https://doi.org/10.1097/coh.0000000000000146
Autor:
Daniel Baty, Cécile Goujard, Craig S. Pace, Mélanie Bouvin-Pley, Martine Braibant, Hugo Mouquet, Patrick Chames, Pascal Poignard, Laurence Meyer, Marion Morgand, Francis Barin, Michel C. Nussenzweig, Pamela J. Bjorkman, Peter D. Kwong, Marie Pancera, David D. Ho, Alain Moreau
Publikováno v:
Journal of Virology. 88:13910-13917
Extending our previous analyses to the most recently described monoclonal broadly neutralizing antibodies (bNAbs), we confirmed a drift of HIV-1 clade B variants over 2 decades toward higher resistance to bNAbs targeting almost all the identified gp1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0a5ba34deaefedca3745d8851935b21c
https://doi.org/10.1128/jvi.02083-14
https://doi.org/10.1128/jvi.02083-14
Autor:
Ming Sun, Michael S. Seaman, Xin Yao, Qihan Li, David D. Ho, Yaoxing Huang, Faye Yu, Neal N. Padte, Craig S. Pace
Publikováno v:
JAIDS Journal of Acquired Immune Deficiency Syndromes. 66:473-483
Although broadly neutralizing monoclonal antibodies (bNAbs) have always been considered to be a potential therapeutic option for the prophylaxis and treatment of HIV infection, their lack of breadth against all HIV variants has been one of the limiti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1c30961b6fa62b8b1221081fa3350d0a
https://doi.org/10.1097/qai.0000000000000218
https://doi.org/10.1097/qai.0000000000000218
Autor:
Peter D. Kwong, Pascal Poignard, Mélanie Bouvin-Pley, Patrick Chames, Pamela J. Bjorkman, Alain Moreau, Marie Pancera, Marion Morgand, Michel C. Nussenzweig, Hugo Mouquet, David D. Ho, François Simon, Francis Barin, Jean-Christophe Plantier, Elodie Alessandri, Craig S. Pace, Martine Braibant, Daniel Baty
Publikováno v:
Journal of Acquired Immune Deficiency Syndromes
Journal of Acquired Immune Deficiency Syndromes, Lippincott, Williams & Wilkins, 2016, 71 (3), pp.237-245. ⟨10.1097/QAI.0000000000000854⟩
Journal of Acquired Immune Deficiency Syndromes-JAIDS
Journal of Acquired Immune Deficiency Syndromes-JAIDS, 2016, 71 (3), pp.237-245. ⟨10.1097/QAI.0000000000000854⟩
Journal of Acquired Immune Deficiency Syndromes (1999)
Journal of Acquired Immune Deficiency Syndromes, Lippincott, Williams & Wilkins, 2016, 71 (3), pp.237-245. ⟨10.1097/QAI.0000000000000854⟩
Journal of Acquired Immune Deficiency Syndromes-JAIDS
Journal of Acquired Immune Deficiency Syndromes-JAIDS, 2016, 71 (3), pp.237-245. ⟨10.1097/QAI.0000000000000854⟩
Journal of Acquired Immune Deficiency Syndromes (1999)
Supplemental Digital Content is Available in the Text.
Background: Highly potent broadly neutralizing monoclonal antibodies (bNAbs) have been obtained from individuals infected by HIV-1 group M variants. We analyzed the cross-group neutralizatio
Background: Highly potent broadly neutralizing monoclonal antibodies (bNAbs) have been obtained from individuals infected by HIV-1 group M variants. We analyzed the cross-group neutralizatio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::106b4a64724fe0b2163b7001f9ebd3cb
https://hal.univ-grenoble-alpes.fr/hal-01314296
https://hal.univ-grenoble-alpes.fr/hal-01314296
Autor:
Craig S. Pace, Jian Yu, Yang Song, Yaoxing Huang, David D. Ho, Gerasimos J. Zaharatos, Sandhya Vasan
Publikováno v:
Vaccine. 30:42-50
Using murine IgG subclass molecules (IgG1 or IgG2a) synthetically fused to HIV-1 or influenza test antigens, we explored the potential for IgG Fc scaffolds to augment immunogenicity. Each antigen (Ag) was grafted onto a hinge-Fc scaffold containing a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::143e98726c7a3a020fb754bf1b7866d6
https://doi.org/10.1016/j.vaccine.2011.10.056
https://doi.org/10.1016/j.vaccine.2011.10.056